Preclinical Medications Discovery and Abuse Liability Testing for NIDA
Active, responses due . Full description on SAM.gov.
Overview
- Response deadline
- 1:00 PM EST
- Posted
- November 13, 2026
- Notice type
- Presolicitation
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH OLAO
- Place of performance
- Bethesda, Maryland
- Last updated
- Nov 13, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75N95022C00004
- Notice ID
- 54f02db654c1489dadd4275bbb1462d9
Description
NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE
- Notice ID: 75N95022C00004
- Contract Opportunity Type: Presolicitation
- Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days)
- Classification: No Small Business Set Aside Used
- Product Service Code: AN11
- NAICS Code: 541715
- Place of Performance: Blank
Description
PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS.
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged.
This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed.
REGULATORY AUTHORITY
The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26.
STATUTORY AUTHORITY
This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements.
CLOSING STATEMENT
THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted.
PRIMARY POINT OF CONTACT:
Shayna Simpson
Email: shayna.simpson@nih.gov
Phone: 301-402-9712
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
No documents available.
Lifecycle
- 1Version 1PresolicitationCurrent
Preclinical Medications Discovery and Abuse Liability Testing for NIDA
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N95022C00004
Archive Date
Dec 12, 2026
Office Address
BETHESDA, MD, 20892